| Name of the Instrument/Tool | Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) |
| First Description |
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. |
| Year | 2002 |
| Domains | |
| Concept of constructs | Disease activity |
| Population/Disease | Disease specific |
| Originally developed for | Systemic Lupus Erythematosus (SLE) |
| Other rheumatic diseases where can be applied (only if validated) |
--- |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English |
| Available in Language | Spanish |
| REFERENCE IDENTIFICATION | |
| Author/s | Gladman DD, Ibañez D, Urowitz MB |
| Title | Systemic lupus erythematosus disease activity index 2000 |
| Journal | J Rheumatol |
| Year | 2002 |
| Vol | 29 |
| Num | 2 |
| Pages | 288-91 |
| Country | Canada |
| Language | English |
| Other references of interest | |
| Link | https://pubmed.ncbi.nlm.nih.gov/30571926/ |
| Brief Description |
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies |
| Link | https://pubmed.ncbi.nlm.nih.gov/27696791/ |
| Brief Description |
Polachek A, Gladman DD, Su J, Urowitz MB. Defining low disease activity in systemic lupus erythematosus. Arthritis Care & Res 2017;69:997-1003. |
| Link | https://pubmed.ncbi.nlm.nih.gov/10685800/ |
| Brief Description |
Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in SLE. J Rheumatol 2000;27:377-379. |
| Instrument/Tool Translations References | |
| Link | https://pubmed.ncbi.nlm.nih.gov/15468356/ |
| Brief Description |
The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus |
| Link | https://pubmed.ncbi.nlm.nih.gov/30895904/ |
| Brief Description |
Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients |
| Link | https://pubmed.ncbi.nlm.nih.gov/33091256/ |
| Brief Description |
Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Dafna D Gladman |
| dafna.gladman@utoronto.ca | |
| Address | The University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada. |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | --- |
| Brief Description |
The SLEDAI 2K is the 2002 version of the original SLEDAI, which was published in 1992. Useful to measure global disease activity from lupus modeled on clinicians’ global judgment including evaluation of specific manifestations in nine organ systems. |
| Number of Items | 24 (16 are clinical; 8 are based on laboratory test results) |
| Range | 0-105 (each item score range from 1 to 8) |
| Responses options/scale |
Yes The SLEDAI 2K scores the presence of any rash, alopecia, and mucosal ulcers and a new, recurrent, or persistent proteinuria (urine protein levels >0.5 gm/24 hours) to capture persistent disease activity to capture persistent disease activity |
| Developed for | Clinical practice, Research |
| PRACTICAL APPLICATION | |
| Method of administration | Physician |
| Recommendations to score |
Individual item scores are simply added to give a global score. Each of the organ system manifestations received a “weighted” score, ranging from 1 to 8, based on its severity. The global score could range from 0 (no disease activity) to 105. Lupus LDA state has been defined as SLEDAI-2K <3 including only 1 clinical manifestation of: rash, alopecia, mucosal ulcers, pleurisy, pericarditis, fever, thrombocytopenia or leukopenia. HDA is defined as SLEDAI-2K>6 |
| Score Interpretation | Higher scores indicate higher disease activity. SLEDAI-2K of 4 identifies patients with a flare. |
| Cut-off points | LDA if SLEDAI 2K < 3 with one clinical manifestation; HDA if SLEDAI 2K > 6 |
| Cut-off points applied to | --- |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | 10 minutes |
| Scoring time by the assessor | SLEDAI 2K cannot be scored until laboratory test results are available minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments | --- |